Freidlin B - Search Results

1

Methods for assessing reproducibility of clustering patterns observed in analyses of microarray data.

McShane LM, Radmacher MD, Freidlin B, Yu R, Li MC, Simon R. McShane LM, et al. Among authors: freidlin b. Bioinformatics. 2002 Nov;18(11):1462-9. doi: 10.1093/bioinformatics/18.11.1462. Bioinformatics. 2002. PMID: 12424117

2

A Bayesian model for evaluating specificity of treatment effects in clinical trials.

Simon RM, Dixon DO, Freidlin B. Simon RM, et al. Among authors: freidlin b. Cancer Treat Res. 1995;75:155-75. doi: 10.1007/978-1-4615-2009-2_8. Cancer Treat Res. 1995. PMID: 7640162 Review. No abstract available.

3

Accelerated titration designs for phase I clinical trials in oncology.

Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC. Simon R, et al. Among authors: freidlin b. J Natl Cancer Inst. 1997 Aug 6;89(15):1138-47. doi: 10.1093/jnci/89.15.1138. J Natl Cancer Inst. 1997. PMID: 9262252

4

Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases.

Becker KG, Simon RM, Bailey-Wilson JE, Freidlin B, Biddison WE, McFarland HF, Trent JM. Becker KG, et al. Among authors: freidlin b. Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):9979-84. doi: 10.1073/pnas.95.17.9979. Proc Natl Acad Sci U S A. 1998. PMID: 9707586 Free PMC article.

5

Trends in reported incidence of primary malignant brain tumors in children in the United States.

Smith MA, Freidlin B, Ries LA, Simon R. Smith MA, et al. Among authors: freidlin b. J Natl Cancer Inst. 1998 Sep 2;90(17):1269-77. doi: 10.1093/jnci/90.17.1269. J Natl Cancer Inst. 1998. PMID: 9731733

6

Increased incidence rates but no space-time clustering of childhood astrocytoma in Sweden, 1973-1992: a population-based study of pediatric brain tumors.

Smith MA, Freidlin B, Ries LA, Simon R. Smith MA, et al. Among authors: freidlin b. Cancer. 2000 Mar 15;88(6):1492-3. doi: 10.1002/(sici)1097-0142(20000315)88:6<1492::aid-cncr30>3.0.co;2-7. Cancer. 2000. PMID: 10717635 No abstract available.

7

Evaluation of randomized discontinuation design.

Freidlin B, Simon R. Freidlin B, et al. J Clin Oncol. 2005 Aug 1;23(22):5094-8. doi: 10.1200/JCO.2005.02.520. Epub 2005 Jun 27. J Clin Oncol. 2005. PMID: 15983399

8

Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients.

Freidlin B, Simon R. Freidlin B, et al. Clin Cancer Res. 2005 Nov 1;11(21):7872-8. doi: 10.1158/1078-0432.CCR-05-0605. Clin Cancer Res. 2005. PMID: 16278411

9

Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect.

Jiang W, Freidlin B, Simon R. Jiang W, et al. Among authors: freidlin b. J Natl Cancer Inst. 2007 Jul 4;99(13):1036-43. doi: 10.1093/jnci/djm022. Epub 2007 Jun 27. J Natl Cancer Inst. 2007. PMID: 17596577 Clinical Trial.

10

The cross-validated adaptive signature design.

Freidlin B, Jiang W, Simon R. Freidlin B, et al. Clin Cancer Res. 2010 Jan 15;16(2):691-8. doi: 10.1158/1078-0432.CCR-09-1357. Epub 2010 Jan 12. Clin Cancer Res. 2010. PMID: 20068112

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

139 results

Search Page

Filters